|
| Press Releases |
|
 |
|
| Thursday, October 30, 2025 |
|
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma |
| more info >> |
|
| Tuesday, October 28, 2025 |
|
|
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma |
| more info >> |
|
| Monday, October 27, 2025 |
|
|
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease |
| more info >> |
|
| Tuesday, October 14, 2025 |
|
|
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that LEQEMBI(R) IQLIK(TM), a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease (AD) has been selected by TIME as one of the "Best Inventions of 2025" in the Medical and Healthcare category. more info >> |
|
| Wednesday, October 8, 2025 |
|
|
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI(R) IQLIK(TM) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Friday, October 3, 2025 |
|
|
Eisai Highlights Breadth of Oncology Research at ESMO 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of clinical research across its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2025, which is taking place in Berlin, Germany from October 17 to 21. more info >> |
|
| Monday, September 29, 2025 |
|
|
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI(R)" (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the National Medical Products Administration (NMPA) in China. more info >> |
|
| Tuesday, January 7, 2025 |
|
|
金沢大とエーザイ、レカネマブがアルツハイマー病の病態進行を抑制するメカニズムの一端を解明 |
| more info >> |
|
| Monday, December 23, 2024 |
|
|
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases |
| Fujirebio Holdings, Inc., a wholly-owned subsidiary of H.U. Group Holdings, Inc., and Eisai Co., Ltd. announced today that they have entered into a memorandum of understanding for the joint research and social implementation of novel blood-based biomarkers in the field of neurodegenerative diseases. more info >> |
|
| Wednesday, September 24, 2025 |
|
|
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI(R)" (brand name, generic name: lecanemab) for mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD) (collectively referred to as early AD) in adults who are either ApoEε4* non-carriers or heterozygous carriers. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
OBIファーマとTegMine Therapeutics、糖鎖標的ADCに関する独占的グローバルライセンス契約を締結
Jan 12, 2026 21:00: JST
|
|
|
浩鼎與 TegMine Therapeutics簽訂醣標靶ADC 全球商業授權合約
Jan 12, 2026 20:00 HKT/SGT
|
|
|
浩鼎与 TegMine Therapeutics 签订醣靶标 ADC 全球商业授权合约
Jan 12, 2026 20:00 HKT/SGT
|
|
|
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
Jan 12, 2026 20:00 HKT/SGT
|
|
|
查理控股（OTCQB:CHUC）與IKE科技簽署協議，將推出革命性年齡驗證電子煙產品以解決FDA對青少年接觸的擔憂
Jan 12, 2026 19:00 HKT/SGT
|
|
|
查理控股公司（OTCQB:CHUC）与IKE科技签署协议，将推出革命性年龄验证电子烟产品以解决FDA对青少年获取渠道的担忧
Jan 12, 2026 19:00 HKT/SGT
|
|
|
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access
Jan 12, 2026 19:00 HKT/SGT
|
|
|
Toys & Games Fair, Baby Products Fair and Stationery & School Supplies Fair open today
Jan 12, 2026 18:26 HKT/SGT
|
|
|
Argentine Football Association (AFA) arbeitet mit Verofax zusammen, um Fans KI-gestützte Erlebnisse zu bieten
Jan 12, 2026 16:00 HKT/SGT
|
|
|
聯想之星與君聯資本所投企業精鋒醫療在港交所成功上市
Jan 12, 2026 14:43 HKT/SGT
|
|
|
联想之星与君联资本所投企业精锋医疗在港交所成功上市
Jan 12, 2026 14:43 HKT/SGT
|
|
|
Mazda Unveils MAZDA CX-6e New Battery EV in World Premiere
Jan 12, 2026 13:10 JST
|
|
|
Argentine Football Association (AFA) se asocia con Verofax para ofrecer experiencias de IA a los aficionados
Jan 12, 2026 10:00 HKT/SGT
|
|
|
Argentine Football Association (AFA), Verofax와 협력 팬을 위한 AI 경험 제공
Jan 12, 2026 10:00 HKT/SGT
|
|
|
Argentine Football Association（AFA）攜手 Verofax 為球迷提供 AI 互動體驗
Jan 12, 2026 10:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
